OPTION-EMEA Clinical Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

Also called NCT07349121

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose other
Phase
Not applicable
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07349121
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, Croatia, France, Italy, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07349121. Allocation not applicable; no masking; primary purpose other. Start 2026-06-18 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
OPTION-EMEA Clinical Trial
Acronym
OPTION-EMEA
Condition
Atrial Fibrillation (AF)
Condition
Stroke Prevention in Patients With Atrial Fibrillation
Condition
Left Atrial Appendage Closure
Condition
Pulsed Field Ablation
Condition
Atrial Fibrillation Ablation Procedure
Condition
Concomitant Procedures
Intervention (Device)
Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case
Intervention (Procedure)
Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct07349121
Content hash
cc5c33d6c5fb58744273455d30e0d543c3f6c14a9e31f5c04521c2b8fc523a35